JCR Pharmaceuticals Co., Ltd.
JCRRF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -12.20 | 0.35 | 0.00 | -1.70 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 2,776.60 | 467.35 | -21.28 | 142.69 |
| Quality | ||||
| ROIC | 2.27% | -0.00% | -8.87% | -0.01% |
| Gross Margin | 84.33% | 72.05% | 39.85% | 70.97% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -27.26% | -11.08% | -1.25% | -2.25% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 5.99 | 134.96 | -4.88 | 22.83 |
| Interest Coverage | 37.78 | -0.26 | -196.53 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.20 | 0.11 |
| Cash Conversion Cycle | 155,509.23 | 137,974.23 | 593.51 | 911.52 |